glp-1 discontinuation rates Most adults with overweight or obesity discontinue therapy within 2 years Discontinuation rates of GLP-1 medications
Description
Interview Courtesy | Ankit Kankar #GLP1 #Diabetes #Obesity #Cardiology #Metabolism #Therapeutics #Innovation #Healthcare #Medicine #Research #Pharmacology #Biotechnology #Clinicaltrials #Prevention #Wellness
GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound have rapidly transformed the management of diabetes and obesity, becoming some of the most requested treatments within employer-sponsored health plans

Learn more and improve your treatment experience.

Its system-level disruption

Your provider will determine the appropriate weekly dose after reviewing your intake form
